APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Inclusion Criteria: * Eligible for and scheduled to receive treatment with commercially available PEG-IFN alfa-2a and ribavirin combination * Serologic evidence of chronic hepatitis C (CHC) infection * Detectable serum hepatitis C virus - ribonucleic acid (HCV-RNA) * Negative urine or blood pregnancy test * Fertile participants receiving treatment to use two forms of effective contraception during treatment and for 6 months after treatment end Exclusion Criteria: * Women with ongoing pregnancy or who are breast feeding, or male partners of women who are pregnant * Received any investigational drug less than or equal to (\</=) 6 weeks prior to enrollment * Moderate hepatic failure \[Child-Pugh greater than or equal to (\>/=) B\] * Co-infection with human immunodeficiency virus (HIV) or hepatitis B * Autoimmune hepatitis * Known hypersensitivity to alfa interferons, E. coli-derived products, polyethylene glycol, ribavirin and/or any ingredient in the formulation or component of PEG-IFN alfa-2a or ribavirin